



For Immediate Release

PATHEON RANKED AS TOP CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION

*Ranking based on independent PharmSource® research detailing number of NDA- and BLA-approved products outsourced to contract manufacturers**

RESEARCH TRIANGLE PARK, N.C. (July 15, 2010) – Patheon (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it has been ranked as a top global contract development and manufacturing organization. PharmSource®, a respected independent pharmaceutical research organization, recently published a study looking at the number of FDA new drug approvals (NDAs and BLAs) which were outsourced by sponsor companies and subsequently launched. The study found that Patheon had the highest number of new drugs overall, and by far the highest number of solid dose drugs over the past four and a half years. The study was conducted independently by PharmSource® and was not commissioned by Patheon.

Wes Wheeler, Patheon’s Chief Executive Officer and President, said, “The results of this research again position Patheon as a leading formulation development company, capable of taking new drugs from the lab all the way to full commercialization. We continue to make strategic investments in pharmaceutical development which now boasts nearly 600 scientists in eight development centers. We will soon have our French development center ready for use, bringing us to nine development centers. Six of these development centers are attached to our commercial scale manufacturing facilities, which allow us to offer a unique, broad-based ‘molecule to market’ service to our customers. We are proud to be working with 19 of the top 20 pharmaceutical companies, 17 of the top 20 specialty pharmaceutical companies and six of the top 10 biotechnology companies. We will continue to invest in our facilities and maintain the highest degree of regulatory compliance as we enter a new age of outsourcing.”

Research Methodology

The PharmSource® research was based on data including all therapeutics approved by the FDA from January 1, 2005 to June 30, 2010 that were outsourced to CMOs. Exactly 200, or 42 percent, of the 475

approvals were outsourced. Of those 200, PharmSource® was able to successfully identify the contract dose manufacturer for 185 of them. The market was segmented into four dosage form categories: solid, semisolid/liquid, injectables, and specialty delivery. In total, 72 different CMOs had at least one of the 200 outsourced FDA approvals granted during the period. The top 12 dose CMOs accounted for 105 of those approvals and Patheon received 20 of the approved products for development.

*JULY 2010 “Top Dose CMOs by Number of NDA and BLA Approvals,” PharmSource®.

ABOUT PATHEON

Patheon is a leading global provider of contract development and manufacturing services to the pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world’s leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon’s comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon’s Quick to Clinic™ programs can accelerate early phase development projects to clinical trials while minimizing the consumption of valuable API. Patheon’s integrated development and manufacturing network of 11 facilities and eight development centers, across North America and Europe, ensures that customer products can be launched timely and confidently anywhere in the world.

Patheon Contacts:

Wes Wheeler

President & Chief Executive Officer

Tel: (919) 226-3200

Email: wes.wheeler@patheon.com

Eric Evans

Chief Financial Officer

Tel: (919) 226-3200

Email: eric.evans@patheon.com

Wendy Wilson

Investor Relations and Corporate Communications

Tel: (919) 226-3313

Email: wendy.wilson@patheon.com

###